"In our clinical trials, Cagrilintide has provided substantial weight loss, in a distinct manner compared to approved obesity medications, and appears well-tolerated," Martin Holst Lange, Novo Nordisk's chief scientific officer and executive vice president of research and development, said in a statement
Although enrichment of the Enterobacteriaceae family may be due, in part, to the increase of pathogenic and opportunistic pathogens, such assumption may not be entirely accurate, or justified, as there are many commensal Gram-negative bacteria that belong to the Enterobacteriaceae family (e.g., strains of E
These products are not intended to diagnose, treat, cure or prevent any disease.
Also, Food & Beverages Industry uses Acetylcarnitine on a big scale